B. Clotet

VLP-mediated delivery of structure-selected neoantigens demonstrates immunogenicity and antitumoral activity in mice

This study develops a neoantigen selection pipeline and a VLP-based vaccine platform to enhance immunogenicity and antitumor activity in mice.

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

Beta-Cyclodextrins as affordable antivirals to treat coronavirus infection

The paper identifies beta-cyclodextrins as effective and affordable antivirals against SARS-CoV-2 and other coronaviruses through molecular modeling and in vitro testing.

Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART

This study identifies a selective loss of CD107a+ TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH on long-term ART, which can be reversed by TIGIT blockade.

Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis

This study uses electron microscopy to show plitidepsin blocks SARS-CoV-2 replication organelles and virus morphogenesis.

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

This paper evaluates a recombinant RBD fusion heterodimer vaccine in mice, showing 100% efficacy against SARS-CoV-2 variants and neutralizing antibodies.

Anti-SARS-CoV-2 hyperimmune immunoglobulin provides potent and robust neutralization capacity and antibody-dependent cellular cytotoxicity and phagocytosis induction through N and S proteins

This study evaluates the neutralization and antibody-dependent cellular effects of anti-SARS-CoV-2 hyperimmune immunoglobulin against multiple SARS-CoV-2 isolates and variants.

Gut Microbiome Signatures Linked to HIV-1 Reservoir Size and Viremia Control

The paper identifies gut microbiome signatures, specifically the Bacteroidales/Clostridiales ratio, associated with HIV-1 reservoir size and viremia control in a clinical trial.

SARS-CoV-2 B.1.351 (beta) variant shows enhanced infectivity in K18-hACE2 transgenic mice and expanded tropism to wildtype mice compared to B.1 variant

This study shows that the SARS-CoV-2 B.1.351 variant infects K18-hACE2 mice faster and wildtype mice, with milder symptoms than the B.1 variant.

Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses

This study shows Siglec-1 on APCs mediates SARS-CoV-2 trans-infection and triggers proinflammatory responses, suggesting it as a potential therapeutic target.

Highly functional Cellular Immunity in SARS-CoV-2 Non-Seroconvertors is associated with immune protection

The paper examines T-cell immunity in SARS-CoV-2 non-seroconvertors, finding high functional T-cell responses and low immune activation correlate with protection from severe disease without seroconversion.

Previous SARS-CoV-2 infection increases B.1.1.7 cross-neutralization by vaccinated individuals.

The paper assesses how prior SARS-CoV-2 infection affects B.1.1.7 cross-neutralization in vaccinated individuals, finding that previously infected individuals show equivalent neutralization against B.1.1.7 compared to the Wuhan strain.

Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in hamsters

This study shows that hamsters infected with SARS-CoV-2 are not fully protected against reinfection with both original and variant isolates, but experience reduced lung disease severity upon re-exposure.

Cetylpyridinium chloride-containing mouthwashes reduce the infectivity of SARS-CoV-2 variants in vitro

This study shows that CPC-containing mouthwashes significantly reduce SARS-CoV-2 infectivity in vitro across variants by disrupting the viral envelope and inhibiting fusion.

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

This study tracks neutralizing antibody levels in COVID-19 patients up to six months post-infection, finding persistent activity in mild cases and a slower decline in hospitalized individuals.

SARS-CoV-2 infection suppresses ACE2 function and antiviral immune response in the upper respiratory tract of infected patients

This study shows SARS-CoV-2 reduces ACE2 activity and antiviral gene expression in the upper respiratory tract, while initially increasing interferon-stimulated genes.

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect after a Drug Repurposing Screen

This study screens existing drugs to identify potent inhibitors of SARS-CoV-2-induced cytopathic effect and viral replication, finding plitidepsin as the most effective clinically approved drug.